Committed to solid profitable growth Investor Introduction March 2026 Presentation Titel Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "p ...

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth-quarter outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development against Q4 2024 [6][15] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the outlook of about 4%-5% growth [6][15] - Adjusted diluted EPS for Q4 was $0.62 at CER, exceeding the outlook of about $0.60, while for the full year, it increased to $2.40 at CER, above the initial outlook [6][15] Business Line Data and Key Metrics Changes - Sample technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [7][16] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [8][16] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, aided by menu expansion and a growing install base [8][16] - The PCR product group saw a decline of 9% at CER in Q4, while the genomics and NGS product group grew 2% at CER, driven by QIAGEN Digital Insights [17] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [18] - In the Americas, sales declined 1% at CER, with the U.S. being flat, partly due to the government shutdown [18] - Asia-Pacific-Japan sales were flat, with a low-teens decline in China, which represents only about 4% of total sales [18] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [7][10] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance its Sample technologies portfolio [10][22] - New product launches and expansions in automation are expected to drive future growth, with a target of $720 million in Sample technologies sales for 2026 [36][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macroeconomic environment and cautious capital spending but expressed confidence in achieving growth targets [35][36] - For 2026, QIAGEN anticipates sales growth of at least 5% at CER and adjusted EPS of at least $2.50 at CER, with expectations for improved funding conditions over the year [29][33] - The company is preparing for new product launches and expects to see gradual improvements in the funding environment for research and academia [69] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and introduced an annual dividend payment while pursuing selective acquisitions [10][20] - The company is reviewing its adjusted operating income margin target of at least 31% for 2028, with expectations for continued margin improvement [19][33] Q&A Session Summary Question: Insights on new product launches and growth expectations - Management highlighted that new product launches, including QIAcuity and QIAstat, are expected to open new markets and contribute to growth, with confidence in achieving targets despite previous delays [40][42] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN remains focused on its growth plan and does not comment on rumors, but is open to discussions that could create shareholder value [48] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and management is committed to finding the best fit for the role [50] Question: Clarification on margin expansion and operating leverage - Management expects significant margin improvement in 2026, despite headwinds from acquisitions and tariffs, driven by gross margin improvements and operational efficiency programs [53][55] Question: Outlook for China and exposure to VBP - Management confirmed limited exposure to China, with expectations for low single-digit to negative growth, and stated that the impact of VBP has been factored into their guidance [58][60] Question: Expectations for QIAstat-Dx placements and growth - Management expressed confidence in achieving growth targets for QIAstat-Dx, with a focus on executing product launches and market penetration [62][64]

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth quarter Outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development expected against Q4 2024 [5][6] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the Outlook of about 4%-5% growth [6][12] - Adjusted diluted EPS for Q4 was $0.62 at CER, exceeding the Outlook of approximately $0.60, while for the full year, it increased to $2.40 at CER, above the initial Outlook [6][12] Business Line Data and Key Metrics Changes - Sample Technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [7][16] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [8][16] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, benefiting from menu expansion and a growing install base [8][16] - QIAcuity saw double-digit growth in consumables, with over 3,200 instruments installed globally [8][16] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [17] - In the Americas, sales declined by 1% at CER, with the U.S. being flat, partly due to the government shutdown [18] - Sales in the Asia-Pacific-Japan region were flat, with a low-teens decline in China, which represents only about 4% of total sales [18] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [7][10] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance its Sample Technologies portfolio [10][22] - New product launches and expansions in automation are expected to drive growth, with a target of $720 million in Sample Technologies sales for 2026 [36][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cautious funding and capital spending environment but expressed confidence in gradual improvement throughout 2026 [35][69] - The company anticipates a sales growth of at least 5% for 2026 and adjusted EPS of at least $2.50 at CER, despite headwinds from discontinued products and competitive pressures [29][33] - Management remains focused on operational efficiency and margin improvement, targeting an adjusted operating income margin of at least 31% by 2028 [19][33] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and introduced an annual dividend payment [10][20] - The company completed the acquisition of Parse Biosciences, enhancing its capabilities in single-cell analysis [22][24] - A new supervisory board member, Mark Stevenson, was welcomed, bringing operational and global life sciences experience [10][11] Q&A Session Summary Question: Insights on new product launches and growth targets - Management indicated that new product launches are expected to open new markets and contribute to growth, with confidence in achieving the $250 million target for digital PCR by 2028 despite previous delays [40][42] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN is focused on executing its solid growth plan and does not comment on rumors [48] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and management is committed to finding the best fit for the role [50] Question: Clarification on margin expansion and operating leverage - Management expects significant margin improvement in 2026, driven by gross margin enhancements and operational efficiency programs, despite headwinds from acquisitions and tariffs [53][55] Question: Outlook for China and exposure to VBP - Management confirmed limited exposure to China, with expectations of low single-digit to negative growth due to market conditions, and stated that VBP has been a factor for several years [58][60] Question: Expectations for QIAstat-Dx placements and growth - Management expressed confidence in achieving the target of over $160 million for QIAstat-Dx in 2026, with a focus on executing product launches and market penetration [62][74]

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth quarter 2025 Outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development expected against Q4 2024 [5][12] - Adjusted diluted EPS for Q4 was $0.62 at CER, surpassing the Outlook of approximately $0.60 [5][12] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the Outlook of 4%-5% growth [5][12] - Adjusted diluted EPS for the full year increased to $2.40 at CER, exceeding the initial Outlook by $0.12 [5][12] Business Line Data and Key Metrics Changes - Sample Technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [6][13] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [7][14] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, aided by menu expansion and a growing install base [7][14] - QIAcuity saw double-digit growth in consumables, with over 3,200 instruments installed globally [7][14] - The bioinformatics business, QIAGEN Digital Insights, continued to grow, bolstered by demand from both research and clinical customers [8][24] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [16] - In the Americas, sales declined by 1% at CER, with the U.S. market remaining flat, partly due to the government shutdown [16] - Asia-Pacific-Japan region sales were flat, with a low-teens decline in China, which represents only about 4% of total sales [16][56] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [6][34] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance Sample Technologies [9][19] - New product launches are expected to contribute significantly to growth, with QIAsymphony Connect and QIAmini targeting automation across various applications [20][68] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cautious funding and capital spending environment but expressed confidence in achieving growth targets due to a strong pipeline of new product launches [32][66] - The company anticipates gradual improvement in the funding environment throughout 2026, with expectations for mid-single-digit growth in the total market [66] - QIAGEN's 2026 Outlook includes sales growth of at least 5% at CER and adjusted EPS of at least $2.50 at CER [26][31] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and plans to continue this trend alongside selective acquisitions [9][18] - The company is reviewing its adjusted operating income margin target of at least 31% for 2028, with expectations for continued margin improvement despite headwinds from tariffs and currency movements [17][31] Q&A Session Summary Question: Insights on new product launches and growth targets - Management highlighted that new product launches are expected to open new markets and contribute to growth, with confidence in achieving the $250 million target for digital PCR by 2028 despite previous delays [37][39] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN remains focused on its growth plan and does not comment on rumors [45] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and updates will be provided as progress is made [46] Question: Margin expansion and operating leverage - Management expects significant margin improvement in 2026, driven by gross margin improvements and operational efficiency programs, despite headwinds from acquisitions and tariffs [49][50] Question: Growth outlook in China - Management confirmed limited exposure to China, with expectations for low single-digit to negative growth due to market conditions and political factors [56][57] Question: QIAstat-Dx placements and respiratory season outlook - Management expressed confidence in achieving growth targets for QIAstat-Dx, with expectations for continued relevance in respiratory testing [71][72]

Financial Data and Key Metrics Changes - The company is experiencing strong trends in diagnostics, particularly with QuantiFERON tests for latent TB detection, approaching $500 million in sales this year [3][4] - The overall business is 90% consumables and 10% instruments, with consumable trends remaining good while instrument sales are lagging due to capital purchase reluctance [10][11] - The company expects about 90 basis points of margin pressure on gross margin for 2025 and a similar amount for 2026 due to tariff mitigation measures [25] Business Line Data and Key Metrics Changes - Diagnostics are performing well, especially with QuantiFERON and QIAstat-Dx tests, while life sciences are facing funding pressures in the U.S. and China [3][4][7] - The sample prep business is holding steady, shipping 2.5 to 3 million kits a year, but instrument sales are facing challenges in the current capital environment [32][33] - The company is launching new products in sample prep, focusing on automation to drive growth amid pressures on manual processes [34][36] Market Data and Key Metrics Changes - Academic customers make up about 15% to 20% of the business, with pharma customers also at 15% to 20%, while applied testing accounts for 5% to 10% [7][8] - The NIH funding situation is improving, but trust needs to be rebuilt among academic customers due to past funding inconsistencies [16][17] - The market for latent TB testing remains underpenetrated, with only 40% conversion, indicating significant growth potential [46][49] Company Strategy and Development Direction - The company aims to achieve $2 billion in sales by 2028, focusing on five growth pillars [29][70] - There is a commitment to disciplined capital deployment, including targeted M&A and returning cash to shareholders through dividends and share repurchases [66][69] - The company is enhancing its digital channels and commercialization presence to support growth [65][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current funding pressures and the need for clarity in the operating environment, particularly regarding pharma budgets and tariffs [8][21] - The company is optimistic about the long-term growth potential in diagnostics and sample prep, despite short-term challenges [3][29] - There is a focus on rebuilding trust with academic customers and ensuring consistent funding flows [16][17] Other Important Information - The company is preparing for potential tariff impacts and has implemented measures to mitigate these effects [24][25] - The introduction of a dividend in 2025 was aimed at providing additional returns to shareholders and responding to shareholder demand for yield [66][67] Q&A Session Summary Question: How has the year played out relative to initial expectations? - Management noted that the year has shown the value of the business, with strong trends in diagnostics and some challenges in life sciences due to funding pressures [3][4] Question: What is the current view on pharma customer conversations? - There is ongoing interest in sample prep products, but funding clarity is needed for capital purchases [9][10] Question: How is the company addressing tariff impacts? - The company has been proactive in preparing for tariffs and expects margin pressure as a result [24][25] Question: What is the outlook for the QuantiFERON product? - The product has a strong market position with ongoing improvements and a significant growth opportunity in latent TB testing [46][49] Question: What is the company's capital deployment strategy? - The company is balancing investments in R&D, targeted M&A, and returning cash to shareholders through dividends and share repurchases [66][69]

Committed to solid profitable growth Investor Introduction Q3 2025 Presentation Titel Forward looking and intended use statements Crucial to advancing science Improving healthcare for all Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, d ...

Financial Data and Key Metrics Changes - Net sales increased by 7% to $534 million, with a 6% growth at constant exchange rates (CER) [10] - Adjusted diluted EPS was $0.60, or $0.62 at CER, exceeding targets due to strong operational profitability improvements [10][13] - Adjusted operating income margin rose to 29.9% of sales, up 1.5 percentage points from the same quarter last year [16][23] Business Line Data and Key Metrics Changes - QIAstat sales grew 41% at CER, driven by strong instrument placements and demand for syndromic testing [11] - QuantiFERON sales increased by 11% CER, with solid gains in The Americas and EMEA [11] - Kayakuity, the digital PCR platform, delivered double-digit CER growth, supported by demand for consumables [12] - Sample Technologies saw flat total sales compared to 2024, but single-digit growth in automated consumables [12][20] Market Data and Key Metrics Changes - Sales in The Americas rose 7% CER, with strong growth in the U.S. and Mexico [22] - EMEA region sales grew 8% CER, led by double-digit growth in France and Italy [22] - Asia Pacific region sales declined 4% CER, with significant drops in China [22] Company Strategy and Development Direction - The company has upgraded its full-year 2025 sales outlook to 4% to 5% net sales growth at CER, up from a previous target of about 4% [13] - The company is focused on creating shareholder value through dividends and share repurchase programs, with a goal of returning at least $1 billion to shareholders by 2028 [14] - Continued investment in innovation and targeted M&A opportunities is emphasized to support growth [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth targets despite a volatile macro environment, citing strong execution and operational efficiency [8][39] - The impact of tariffs and currency movements is acknowledged, with ongoing strategies to mitigate these effects [40][84] - Management remains realistic yet ambitious about growth, particularly in the context of core sales performance [49][106] Other Important Information - The company has initiated a dividend payment and has authorization for a synthetic share repurchase of up to $500 million over the next 18 months [14] - The company is on track to achieve $1.49 billion in aggregated sales from its five growth pillars in 2025, representing about 8% growth over the prior year [37] Q&A Session Summary Question: What drives confidence in the guidance for Q3 given tougher comps? - Management noted that while growth is high, the guidance reflects a realistic view of the volatile environment, with a focus on core growth rates [47][49] Question: Can you unpack the 41% growth in QIAstat? - Management indicated that respiratory testing drives the majority of growth, with contributions from GI and meningitis panels, and noted strong instrument placements in the U.S. [54][56] Question: What is included in the "Other" product group? - Management clarified that "Other" includes various factors like freight reimbursements and one-time deals, with a significant impact from discontinued products [60][62] Question: How is the M&A pipeline looking? - Management confirmed a solid pipeline for M&A opportunities, focusing on synergistic deals that create shareholder value [88][90] Question: What are the expectations for Kayakuity in H2? - Management expressed confidence in achieving targets despite cautious capital spending in research and academia, emphasizing the attractiveness of the market [66][70]

Financial Data and Key Metrics Changes - Net sales increased by 7% to $534 million, with a 6% growth at constant exchange rates (CER) [8][12] - Adjusted diluted EPS was $0.60, or $0.62 at CER, exceeding targets due to strong operational profitability improvements [8][12] - Adjusted operating income margin rose to 29.9% of sales, up 1.5 percentage points from the same quarter last year [15][22] Business Line Data and Key Metrics Changes - QIAstat sales grew by 41% at CER, driven by strong instrument placements and demand for syndromic testing [9][19] - QuantiFERON sales increased by 11% at CER, with solid gains in The Americas and EMEA [9][19] - Kayakuity, the digital PCR platform, experienced double-digit CER growth, although instrument placements were slightly below the previous year [10][19] - Sample Technologies sales were flat compared to 2024, but automated consumables showed single-digit growth [11][19] Market Data and Key Metrics Changes - Sales in The Americas rose by 7% CER, supported by strong growth in the U.S. and Mexico [21] - EMEA region sales grew by 8% CER, led by double-digit growth in France and Italy [21] - Asia Pacific region sales declined by 4% CER, with significant drops in China [21] Company Strategy and Development Direction - The company has upgraded its full-year 2025 sales outlook to 4% to 5% net sales growth at CER, up from a previous target of about 4% [12][36] - The company is focused on returning at least $1 billion to shareholders by 2028, with plans for a synthetic share repurchase of up to $500 million [13][39] - Continued investment in organic growth and innovation, alongside targeted M&A opportunities [13][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving upgraded targets despite a complex macro environment [12][36] - The impact of tariffs is expected to create a headwind of about 90 basis points on adjusted gross margin [37][83] - Management remains realistic yet ambitious regarding growth, particularly in light of the discontinuation of certain products [46][106] Other Important Information - The company has maintained a strong balance sheet, allowing for flexibility in investments and shareholder returns [18][39] - R&D investments were 8.9% in Q2 2025, aligned with annual targets [23] - The company is actively reviewing refinancing opportunities for convertible notes due in H2 2025 [26] Q&A Session Summary Question: What drives confidence in the guidance for Q3 given tougher comps? - Management noted that the guidance reflects a strong performance and emphasized the importance of core growth rates in Q4 due to product discontinuations [45][46] Question: Can you elaborate on the 41% growth in QIAstat? - Management indicated that respiratory testing drives most of the growth, with contributions from GI and meningitis panels, and highlighted strong instrument placements [52][54] Question: What is included in the "Other" product group? - Management clarified that "Other" includes various factors, with a significant impact from discontinued products, specifically NeuMoDx [57][59] Question: How is the M&A pipeline looking? - Management confirmed a solid pipeline for M&A opportunities, focusing on synergistic deals that create shareholder value [88][90] Question: What are the expectations for QIAcuity in the second half of the year? - Management expressed confidence in achieving targets despite cautious capital spending in research and academia [64][66]